Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G R Wilkinson

Showing results (91-100 of 190) with videos related to

Pageof 19
Sort By:
Cancer Chemotherapy and Pharmacology|July 19, 2001
In vivo inhibition of human CYP1A2 activity by oltiprazG G Sofowora, E F Choo, G Mayo, et al.
Clinical Pharmacology and Therapeutics|April 1, 1989
Influence of debrisoquin phenotype on the inducibility of propranolol metabolismO Shaheen, J Biollaz, R P Koshakji, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1991
Geometric isomerization of doxepin during its N-demethylation in humansH Ghabrial, C Prakash, U G Tacke, et al.
Pharmacogenetics|June 1, 1992
The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancerC M Fleming, A Kaisary, G R Wilkinson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 27, 1999
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadineM Cvetkovic, B Leake, M F Fromm, et al.
Clinical Pharmacology and Therapeutics|January 1, 1989
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activitiesS A Ward, T Walle, U K Walle, et al.
British Journal of Clinical Pharmacology|October 1, 1987
Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in manC Funck-Brentano, P L Chaffin, G R Wilkinson, et al.
Biochimica Et Biophysica Acta|January 16, 1999
Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variantsM F Fromm, B Leake, D M Roden, et al.
British Journal of Clinical Pharmacology|September 1, 1991
Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphismJ Turgeon, W E Evans, M V Relling, et al.
Biochemistry|June 5, 1984
Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolismD Larrey, L M Distlerath, G A Dannan, et al.
Pageof 19

Showing results (91-100 of 190) with videos related to

Sort By:
Pageof 19
Cancer Chemotherapy and Pharmacology|July 19, 2001
In vivo inhibition of human CYP1A2 activity by oltiprazG G Sofowora, E F Choo, G Mayo, et al.
Clinical Pharmacology and Therapeutics|April 1, 1989
Influence of debrisoquin phenotype on the inducibility of propranolol metabolismO Shaheen, J Biollaz, R P Koshakji, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 1, 1991
Geometric isomerization of doxepin during its N-demethylation in humansH Ghabrial, C Prakash, U G Tacke, et al.
Pharmacogenetics|June 1, 1992
The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancerC M Fleming, A Kaisary, G R Wilkinson, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 27, 1999
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadineM Cvetkovic, B Leake, M F Fromm, et al.
Clinical Pharmacology and Therapeutics|January 1, 1989
Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activitiesS A Ward, T Walle, U K Walle, et al.
British Journal of Clinical Pharmacology|October 1, 1987
Effect of oral administration of a new calcium channel blocking agent, bepridil on antipyrine clearance in manC Funck-Brentano, P L Chaffin, G R Wilkinson, et al.
Biochimica Et Biophysica Acta|January 16, 1999
Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variantsM F Fromm, B Leake, D M Roden, et al.
British Journal of Clinical Pharmacology|September 1, 1991
Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphismJ Turgeon, W E Evans, M V Relling, et al.
Biochemistry|June 5, 1984
Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolismD Larrey, L M Distlerath, G A Dannan, et al.
Pageof 19